Phaseline

Targets › ALMS1

ALMS1 (Centrosome-associated protein ALMS1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2027.

Involved in PCM1-dependent intracellular transport. Required, directly or indirectly, for the localization of NCAPD2 to the proximal ends of centrioles. (UniProt, Q8TCU4)

Open in Phaseline: the race on ALMS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AdipoPharmaPATAS Trifluoroacetate
Modulator of ALMS1-PKC alpha interaction
ALMS1, PRKCAPhase 1Type 2 DiabetesMay 2027

Conditions

Type 2 Diabetes (1)

Modalities

small molecule (1)

Companies

AdipoPharma (1)

Related targets

PRKCA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.